ILUVIEN AccessPlus Program offers streamlined patient reimbursement support services that is easily integrated into your patient processing system. ILUVIEN AccessPlus supports your patients with comprehensive services built around your practice needs:
Alimera is committed to supporting your practice. Our Field Reimbursement Managers are available to partner with you as you navigate the ILUVIEN reimbursement process.
Phone: 1-844-445-8843, Option 3
Let us help you determine your patients’ coverage for ILUVIEN
Field Reimbursement Managers are dedicated to providing proactive reimbursement support to your practice for patient coverage scenarios, including:
ILUVIEN offers programs to support patient access: ILUVIEN CoPay and ILUVIEN Patient Assistance.
The ILUVIEN CoPay Program provides assistance toward product-specific copay, co-insurance and insurance deductibles for ILUVIEN that exceed $25.* Qualifying patients are responsible for a maximum of $25.00 out-of-pocket costs.
To help your patients with their out-of-pocket costs for ILUVIEN, the ILUVIEN CoPay Program is available for eligible patients who have commercial or private insurance. There is no income eligibility requirement and no maximum assistance level. Eligibility requirements include:
*The program does not cover or provide support for procedures, supplies, or physician-related services associated with ILUVIEN. Only product-specific copay, co-insurance and insurance deductibles are covered. This program is not valid where prohibited by law, taxed or restricted. Alimera Sciences reserves the right to change or cancel this offer or eligibility terms at any time without notice.
The ILUVIEN Patient Assistance Program provides ILUVIEN free of charge to eligible patients who are uninsured or lack coverage for ILUVIEN. Eligibility requirements include:
The process:
There are a number of acquisition options for ILUVIEN. Choose the one that best suites your practice.
Besse Medical Ophthalmology
1-888-767-7123 | View Besse online catalog | ILUVIEN Order No. 44083
McKesson Specialty Health
1-855-477-9800 | View McKesson’s Ophthalmology site | ILUVIEN Order No. 5004970
Veterans Administration Drug Acquisition: McKesson Plasma and Biologics LLC
Phone Orders: 1-877-625-2566 | Fax Orders: 1-888-752-7626 | Email: mpborders@McKesson.com | Online: Connect.McKesson.com ILUVIEN Order No. 3428968
Department of Defense Drug Acquisition: DMS Pharmaceutical Group, Inc.
(Accessible through DoD web portal)
Consignment Replacement
See options here
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
CONTRAINDICATIONS
Contraindications
Warnings and Precautions
Adverse Reactions
Please see full Prescribing Information.
Tel: 1-844-445-8843, Option 3
Summary Overview of AccessPlus
This site is intended for US residents only. ILUVIEN is a registered trademark of Alimera Sciences, Inc.
CONTINUOUS MICRODOSING and the CONTINUOUS MICRODOSING symbol are trademarks of Alimera Sciences, Inc.
1-844-445-8843. US-ILV-MMM-0538
Consider ILUVIEN for phakic patients with DME, particularly those aged > 50 years and/or with developing cataracts
Patients with diabetes are 2 to 5 times more prone to cataract development2
In the ILUVIEN Phase 3 clinical trials:
Observations from a small, real-world cohort of vitrectomized patients with DME treated with ILUVIEN
Authors of this study received compensation from Alimera. Two authors received speaker honoraria from Alimera, and two authors were consultants. One author received reimbursement of travel expenses and study support from Alimera.
FAME A and B were randomized, double-masked, sham injection-controlled, parallel-group, multicenter studies conducted under a single protocol over 36 months.
Study arms:
956 subjects randomized 2:2:1
Primary endpoint:
Proportion of subjects with improvement in BCVA ≥ 15 letters at 24 months
Inclusion criteria:
Foveal thickness ≥ 250 μm despite ≥ 1 prior focal/grid macular laser photocoagulation treatment and BCVA in ETDRS letter score between 19 and 68 (20/50–20/400).
Exclusion criteria:
Glaucoma, ocular hypertension, IOP > 21 mm Hg, or using IOP-lowering drops.
References:
1. ILUVIEN® [package insert]. Alpharetta, GA: Alimera Sciences, Inc.
1. ILUVIEN® [package insert]. Alpharetta, GA: Alimera Sciences, Inc.
2. Parrish RK, Campochiaro PA, Pearson PA, Green K, Traverso CE, FAME Study Group. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. Ophthalmic Surg Lasers Imaging Retina. 2016;47:426-435.
1. Meireles A, Goldsmith C, El-Ghrably I, et al. Efficacy of 0.2 µg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. Eye (Lond). 2017;31(5):684-690.
1. ILUVIEN® [package insert]. Alpharetta, GA: Alimera Sciences, Inc.
2. Javadi MA, Zari-Ghanavati S. Cataracts in diabetic patients: A review article. J Ophthalmic Vis Rec. 2008;3(1):52-65.
3. Data on file. Alimera Sciences, Inc.
4. Mordi JA, Ciuffreda KJ. Statis aspects of accommodation: age and presbyopia. Vision Res. 1998;38:1643-1653.
5. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626-635.
6. Yang Y, Bailey C, Holz FG, et al. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye (Lond). 2015;29:1173-1180.
1. Data on file. Alimera Sciences, Inc.
1. Data on file. Alimera Sciences, Inc.